Related Experiment Video
Updated: Sep 25, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Ascending Flaccid Paralysis Secondary to Hypokalemia in A Cancer Patient using Abiraterone - A Case Report
Daniella Cristina Brites de Almeida1, Aline Luiza Costa2, Barbara Lacerda de Oliveira Faria3
1Center for Intensive Care Instituto Mario Penna, Hospital Luxemburgo, Belo Horizonte, Minas Gerais, Brazil.
Background:
Prostate cancer (PC) is the most common type of neoplasm in men and the fourth leading cause of mortality in Brazil. The prostate cancer refractory metastatic castration can be treated with abiraterone acetate (AA).
Case Presentation:
Its use has been associated with increased survival. However, there are also side effects associated with the use of this drug, such as severe electrolyte disturbances.
Conclusion:
The objective is to report the clinical case of a patient with castration-resistant metastatic prostate cancer who developed ascending flaccid paralysis secondary to severe hypokalemia, probably due to hyperaldosteronism secondary to the use of Abiraterone Acetate, despite the use of Prednisone.
Related Concept Videos
Nursing Assessment of the Genitourinary System II: Inspection and Palpation
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury III: Clinical Manifestations
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury I: Introduction
Antihypertensive Drugs: Potassium-Sparing Diuretics
